Compare XFLT & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XFLT | OBIO |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.3M | 253.9M |
| IPO Year | 2017 | 2020 |
| Metric | XFLT | OBIO |
|---|---|---|
| Price | $18.93 | $4.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | 61.3K | ★ 300.8K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 14.17% | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $3.02 | $2.20 |
| 52 Week High | $19.63 | $5.78 |
| Indicator | XFLT | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.48 | 53.81 |
| Support Level | $17.03 | $3.83 |
| Resistance Level | $19.53 | $5.42 |
| Average True Range (ATR) | 0.27 | 0.33 |
| MACD | -0.10 | -0.06 |
| Stochastic Oscillator | 36.27 | 40.94 |
XAI Octagon Floating Rate & Alternative Income Trust is a diversified, closed-end management investment company which invests in a dynamically managed portfolio of floating-rate credit instruments and other structured credit investments within the private markets. The Trust's investment objective is to seek attractive total return with an emphasis on income generation across multiple stages of the credit cycle.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.